Nodal Metastases Associated With Fusion Oncogenes Are Age Dependent in Young Adult Patients With Thyroid Cancer
An erratum to this article was published (J Clin Endocrinol Metab, 19 Apr 2024 ↗)
Authors' conclusion
Adult PTC patients under 25 years with fusion oncogenes showed a tendency toward advanced tumor stage and lower thyroid differentiation. Integrating onset age together with oncogenic alterations is worthwhile when managing adult PTC patients.
Study context
- Population
- Papillary thyroid cancer (PTC) patients aged 17∼35 years with established tumor-node-metastasis stages150 tumors
- Participants
- 142 patients
- Exposure
- Fusion oncogenes and aggressive tumor behavior by age tier
- Outcome
- Oncogenic drivers among 150 PTCs and their association with nodal metastasis by age
Methodological detailsDNA and RNA sequencing of a target panel, transcriptome analysis in PTCs with RET fusions
- DNA and RNA sequencing of a target panel
- Transcriptome analysis in PTCs with RET fusions
Main finding
As reported in the abstract
BRAF V600E
n = 105
RET fusions
n = 15
NTRK3 fusions
n = 8
BRAF fusions
n = 4
Observational data: associations, not effects.
Further findings
| Outcome | <25 years | P value |
|---|---|---|
| Advanced tumor stage, <25 vs >25 yearsMarginal increase | 75.00% | P = 0.0646 |
- Lateral lymph node metastasis by age tier · <25 years vs 30∼35 years · risk increased with younger age (75.00% vs 27.27% vs 8.33%)
- P = 0.0369
- Advanced tumor stage, <25 vs >25 years: >25 years 21.74%
Thyroid differentiation score (TDS) and transcriptome
- Fusion oncogenes and age <25 years: lowest TDS; immunoglobulin production and immune response mediator genes significantly upregulated
Original publication
Nodal Metastases Associated With Fusion Oncogenes Are Age Dependent in Young Adult Patients With Thyroid Cancer. J Clin Endocrinol Metab. Published 3 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →